Terns Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone, and welcome to our conversation here with Terns Pharmaceuticals. We have Mark Vignola, CFO. We have Erin Quirk, President and Head of R&D. Thanks so much for joining us today.
Maybe first, we could just go with an overview. So if you could give us a brief overview of the pipeline particularly focused on what you see as key value drivers over the next 12 to 24 months.
Sure, happy to do that. So I'll start off by just saying thanks to the Goldman team and to Corinne for the opportunity here. It's really great to be back here at this conference.
So as you know, Terns is working on three internally discovered compounds of three important mechanisms of action, each of which are clinically validated in three areas of high unmet need overall. So we have TERN-701, our allosteric BCR-ABL inhibitor currently in Phase 1 with our partner Hansoh in China. Hansoh had status update for their ongoing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
